10 December 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the "Company")
Admission of New Ordinary
Shares and New ISIN
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the biopharmaceutical company developing innovative
therapies for blood diseases, wishes to provide a further update on
the admission of the New Ordinary Shares (as defined below) further
to the passing of all resolutions at its Extraordinary General
Meeting (the "Meeting") held on 9 December 2024.
At the Meeting, resolutions were
passed to approve the subdivision and reclassification of the
Company's existing 1,401,815,988 ordinary shares (the "Existing
Ordinary Shares") by 1:2 so that each Existing Ordinary Share was
subdivided and reclassified into 1 new ordinary share of £0.000025
each (the "New Ordinary Shares") and 1 deferred share of £0.009975
each (the "Deferred Shares"), followed by a consolidation of the
New Ordinary Shares by 400:1 so that every 400 New Ordinary Shares
were consolidated into 1 New Ordinary Share of £0.01 each (the
"Capital Reorganisation"). As a result of the approval of the
Capital Reorganisation, the Company has 3,504,539 New Ordinary
Shares in issue.
Admission in respect of such New
Ordinary Shares to the transition category of the Official List of
the FCA and to trading on the Main Market for listed securities of
the London Stock Exchange will become effective and dealings in
those New Ordinary Shares is expected on 13 December 2024. As a
result of the Capital Reorganisation, the ISIN of the New Ordinary
Shares will change from GB00BYX3WZ24 to
GB00BQVXM815.
The Deferred Shares have no right to
vote or participate in the capital of the Company (save as set out
in the Company's Articles of Association) and the Company will not
issue any certificates or credit CREST accounts in respect of them.
The Deferred Shares will not be admitted to trading on any
exchange.
The rights of the New Ordinary
Shares and the Deferred Shares are set out in the new Articles of
Association as adopted by the Company on 9th December
2024.
The above figure of 3,504,539 should
be used by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency
Rules.
Enquiries:
|
Hemogenyx
Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief Executive Officer
& Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP Angel
Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre, Adam
Cowl
|
|
|
|
|
|
Peterhouse
Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as a platform technology
that it uses as an engine for novel product development.